Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: MG data of field sample in Yangze

PROVIDER: PRJNA1243710 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32910800_1.fastq.gz	Fastqsanger.gz
	SRR32910800_2.fastq.gz	Fastqsanger.gz
	SRR32910801_1.fastq.gz	Fastqsanger.gz
	SRR32910801_2.fastq.gz	Fastqsanger.gz
	SRR32910802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 62

Similar Datasets

Project description:Antarctic biological sample data MG-DA

| PRJNA1286158 | ENA

Project description:MT data of field sample in Yangze

| PRJNA1243864 | ENA

Project description:Bohai and Yellow Seas biological sample data MG-DA

| PRJNA1286163 | ENA

MiRNA-seq in blood of myasthenia gravis (MG) patients responder and non-responder to immunosuppressive treatment

Project description:Purpose: to identify specific miRNAs as biomarkers associated with immunosuppressive treatment response in MG patients. Methods: Blood miRNome profiles of 15 responder and 15 non-responder MG patients by miRNA-seq using Illumina NextSeq 500 sequencing. Raw data were de-multiplexed and FASTQ files for each sample were generated using the bcl2fastq software. FASTQ data were checked using the FastQC tool. After mapping the data and counting to relevant entries in miRBase 20 (http://www.mirbase.org/), the numbers of known microRNAs was calculated.For statistical analysis, along with TPM normalization, the trimmed mean of M-values (TMM) normalization method was used. Validation was perfomed using TaqMan Advanced real-time PCR on microRNA array cards. Results: An average of 9.98 million reads was obtained per sample. We identified 41 statistically significant differentially expressed miRNAs (logFoldChange from +1.371 to -1.439, p < 0.05), including 18 miRNAs up-regulated and 23 miRNAs down-regulated in non-responder versus responder MG patients. 23 miRNAs were selected for validation. Among them, three miRNAs were significantly decreased in non-responder versus responder patients, whereas two showed an opposite trend. Conclusions: We identified a blood miRNA signature associated with drug responsiveness in MG patients, that could represent a valuable tool for therapeutic follow-up in MG.

2020-05-23 | GSE131703 | GEO

Pre-treatment expression data from patients recruited to the paclitaxel arm of the CTCR-OV01 study

Project description:All patients with suspected ovarian cancer (Raised CA 125 and a complex pelvic mass in a perimenopausal woman) were radiologically staged using CT scan and a chest x-ray. Patients with evidence of intra-abdominal metastasis and/or malignant pleural effusion were approached for entry to the study. Tissue biopsy was obtained either under radiological control (core needle biopsy) or via laparoscopic surgery (punch biopsy). Patients with histologicaly confirmed epithelial ovarian cancer were randomized to receive either three cycles of carboplatin (AUC 7) or paclitaxel (175 mg/m2). Following data filtering, only 3426 genes were retained for further downstream analysis (see 'Data_after_filtering.txt' at the foot of this record). For data filtering details, please see the 'Data processing' field in any of the associated Sample records. Keywords: Prospective Randomized trial

2007-10-30 | GSE9455 | GEO

Infinium MethylationEPIC BeadChip array data for HGSOC PH039 PDXs at baseline and treated with cycles of 100 mg/kg niraparib for 21 days for four treatment rounds and murine sample.

Project description:Infinium MethylationEPIC BeadChip array data for HGSOC PH039 PDXs at baseline and treated with cycles of 100 mg/kg niraparib for 21 days for four treatment rounds and murine sample.

2021-06-16 | GSE165050 | GEO

Project description:MG data of dilution

| PRJNA1264748 | ENA

Transcription profiling of human patients recruited to the paclitaxel arm of the CTCR-OV01 study, pre-treatment individuals with ovarian cancer

2008-06-16 | E-GEOD-9455 | biostudies-arrayexpress

Advanced mass spectrometry workflows for accurate quantification of trace-level host cell proteins in drug products: benefits of FAIMS separation and gas-phase fractionation DIA

Project description:In this study, we investigated the benefits of adding high-field asymmetric ion mobility spectrometry (FAIMS) separation prior to data dependent acquisition (DDA) and gas phase fractionation (GPF) prior to data independent acquisition (DIA) LC-MS/MS analysis. Native digestion followed by LC-MS/MS with FAIMS allowed the identification of 221 HCPs among which 158 were reliably quantified for a global amount of 880 ng/mg of NIST mAb Reference Material. Our methods have also been applied to commercial DPs and demonstrate their ability to dig deeper into the HCP landscape with the identification of 60 and 67 HCPs, and accurate quantification of 29 and 31 of these impurities in nivolumab and trastuzumab respectively, with sensitivity down to the sub-ng/mg of mAb level.

2023-05-07 | PXD039582 | Pride

Advanced mass spectrometry workflows for accurate quantification of trace-level host cell proteins in drug products: benefits of FAIMS separation and gas-phase fractionation DIA

2023-05-07 | PXD039585 | Pride